title: Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats.
abstract: Scutellarin is an active molecule existing in Erigeron breviscapus (vant.) Hand-Mazz. The present work was designed to study the antiischemic effects of scutellarin and its mixture with another substance, breviscapine, in male Sprague-Dawley (SD) rats. Ligature of left anterior descending arteries was performed to induce acute myocardial infarction (MI), and the middle cerebral artery occlusion was created to induce focal cerebral ischemia. The MI size was significantly reduced by scutellarin (15 and 50 mg/kg) but not by breviscapine (5 to 50 mg/kg); the effect of scutellarin on the anti-MI was dose-dependent. Compared with control group, scutellarin (50 mg/kg) reduced the myocardium cell apoptosis in MI rats. The two drugs together (5 to 50 mg/kg) significantly reduced infarction size in focal brain ischemic rats (P < 0.05). There were no significant differences among the 3 dosages in breviscapine-treated rats, and the effect of scutellarin on the anticerebral ischemia was dose-dependent. The results demonstrate that the protective effects of scutellarin on cardiovascular and cerebrovascular ischemia were better than its mixture, breviscapine, in rats.
authors: Department of Pharmacology, Second Military Medical University, Shanghai, China.
authors: Li-Li
authors: LL
authors: Lin
authors: Ai-Jun
authors: AJ
authors: Liu
authors: Jian-Guo
authors: JG
authors: Liu
authors: Xue-Hong
authors: XH
authors: Yu
authors: Lu-Ping
authors: LP
authors: Qin
authors: Ding-Feng
authors: DF
authors: Su
mesh_terms: D000818:Animals; D047310:Apigenin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy*; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005419:Flavonoids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005965:Glucuronates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D020244:Infarction, Middle Cerebral Artery; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy; D017202:Myocardial Ischemia / Q000188:drug therapy*; D009206:Myocardium / Q000166:cytology; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D023382:Toxicity Tests, Acute
chemical_list: D002316:Cardiotonic Agents; D004338:Drug Combinations; D005419:Flavonoids; D005965:Glucuronates; D018696:Neuroprotective Agents; C061097:breviscapine; C484876:scutellarin; D047310:Apigenin